Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Biofrontera Inc BFRI
$1.18
▼ -1.67%
($-0.02)
Open
$1.20
Prev Close
$1.20
Day Range
$1.16 – $1.23
52W Range
$0.56 – $1.66
Market Cap
$17.53M
Beta
0.83
EPS (TTM)
$-0.59
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-10-14 |
| Shares Out. | 12,800,000 |
| Website | biofrontera-us.com/ ↗ |
| Phone | 17812451325 |
| Employees | 94 |
| Revenue | $12.0M |
| Gross Profit | $9.6M |
| Net Income | -$604,000 |
| Free Cash Flow | -$7.9M |
| Total Assets | $24.1M |
| Total Liabilities | $18.1M |
| Equity | $6.0M |
About Biofrontera Inc
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
Biofrontera Inc is a publicly traded company under the ticker symbol BFRI on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-09-01)